A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Inclusion Criteria:

Main Study:

• Eligible participants must be Chinese.

• Participant has had moderately to severely active UC diagnosed at least 3 monthsprior to first investigational product administration.

Open-label Extension Period:

• Participants who have completed the Week 10 Visit and are non-responders at Week 10.

• Participants who have completed the Induction Period and entered the MaintenancePeriod experienced disease relapse during the Maintenance Period, or who havecompleted the Maintenance Period at Week 52.

Exclusion Criteria:

Main Study and Open-label Extension Period:

• Participant has severe extensive colitis, diagnosis of CD, indeterminate colitis,presence or history of a fistula consistent with CD, microscopic colitis, radiationcolitis, or ischemic colitis.

Open-label Extension Period:

• Participant has clinically relevant hepatic, neurological, pulmonary,ophthalmological, endocrine, psychiatric, or other major systemic disease makingimplementation of the protocol or interpretation of the study difficult or thatwould put the participant at risk by continuing the study or that would haverequired a participant to discontinue treatment were observed during the InductionPeriod or Maintenance Period.

• Participant has clinically relevant cardiovascular conditions, including history orpresence of recent myocardial infarction, unstable angina, stroke, transientischemic attack, decompensated heart failure requiring hospitalization, Class III/IVheart failure, sick sinus syndrome, or severe untreated sleep apnea were observedduring the Induction Period or Maintenance Period.